Review of NICE Technology Appraisal Guidance No 117; Cinacalcet for the treatment of hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

The Institute was proposing that the review of the original guidance be deferred until results of the on-going EVOLVE trial are available.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as Appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

We will therefore defer the review of the original guidance until the results of this trial are available. At this point the evidence base will again be assessed to ascertain the need for a review of the current guidance.

May 2010